At 1 year, leaflet transcatheter mitral valve repair demonstrated low rate of complications, high survival and sustained mitral regurgitation reduction, according to results of the CLASP study presented at the virtual PCR e-course.
Also presented at the virtual meeting, researchers reported on the safety and efficacy of the first-in-human trials of transseptal transcatheter mitral valve replacement for mitral regurgitation among high-risk patients.
“At 1 year, the Pascal transcatheter repair system resulted in high survival and low complication rates with robust and sustained mitral regurgitation reduction, accompanied by significant improvements in functional status and quality of life,” John Webb, MD, medical director of the catheterization lab at St. Paul’s Hospital in Vancouver, Canada, and colleagues wrote in the study that was simultaneously published in JACC: Cardiovascular Interventions. “Analysis by etiology showed similar favorable results in patients with functional mitral regurgitation or degenerative mitral regurgitation. The CLASP IID/IIF randomized clinical trial is underway.”
Click here for the full story on Healio.